Pod Insights Pharmacy Podcast Network Pharmacogenomics in Pharmacy: How Dr. Josiah Allen is Leading the Future of Precision Medicine | PharmXcel Podcast About this episode Want to break into pharmacogenomics and precision medicine? In this episode, I sit down with Dr. Josiah Allen, a precision medicine pharmacist with nearly 20 years of experience in genomics, psychiatry, and clinical research. We explore how pharmacogenomics is revolutionizing patient care, prescribing, and the role of pharmacists in the future of medicine. We cover: • How Josiah transitioned from industry to clinical practice in pharmacogenomics • The multidisciplinary approach to precision medicine at St. Elizabeth Healthcare • Why pharmacists are the ideal leaders in pharmacogenomics • The future of personalized medicine and emerging fields beyond PGx • How to successfully implement pharmacogenomics in a healthcare setting • The importance of patient empowerment, education, and shared decision-making If you're a pharmacist looking to future-proof your career and expand into precision medicine, this episode is a must-listen! Join the ElevateRx Pharmacogenomics Summit to learn how to bring Pharmacogenomics to your practice - https://elevaterx.live/ Follow Dr Josiah Allen [https://www.linkedin.com/in/allenjosiah] on LinkedIn About me:👉 Visit www.apma.website to learn how I teach pharmacists the role of genes in medication response inside the Australasian Precision Medicine Academy. 👉 Visit www.katrinaazer.com to find out more about my services. Follow me on social media: ➡️ LinkedIn: https://www.linkedin.com/in/katrina-azer/ ➡️ Facebook: https://www.facebook.com/katrina.azer/ The PharmXcel Podcast is a show for pharmacists who want to connect with their career purpose and learn how to build a fulfilling career by addressing the opportunities and challenges that make us pharmacists—Pharmacists who signed up for pharmacy to help transform patient lives! Thanks for listening in—it means the world to me! Here is how you can support my mission: Give it a 5-star rating wherever you’re listening to it Share this with other Pharmacists who would enjoy it Subscribe to get notified of new episodes And please reach out if you have any questions or comments! Your feedback will help me bring you valuable content
Transcript 0:05 Speaker 00 In today's fast-paced pharmaceutical landscape, having a reliable partner is crucial for the success of independent and specialty pharmacies. That's where FH2 Pharma comes in.
0:17 Speaker 01 Founded in 2018 by industry leaders, FH2 Pharma recognized the need for virtual pharmaceutical companies specializing in generics. Their mission: to ensure that the independent and specialty pharmacies have consistent access to unique dosage formulations of generic medications.
0:34 Speaker 00 What sets FH2 Pharma apart? Every product they offer is proudly manufactured in the United States, ensuring top-notch quality and reliability. This commitment means pharmacies can depend on a predictable product supply, even amidst market fluctuations.
0:53 Speaker 01 But it's not just about supply. FH2 Pharma's unique dosage formulations are designed to meet specific patient needs, allowing for more flexible prescribing and better patient outcomes. Plus, their focus on specialty and independent pharmacies means they're dedicated to improving your profit margins.
1:10 Speaker 00 Imagine reducing margin-loss prescriptions by offering unique dosages at improved margins. With FH2 Pharma, this isn't just a possibility, it's a reality.
1:22 Speaker 01 Ready to enhance your pharmacy's offerings? Contact FH2 Pharma today to discuss partnerships, stocking their products, or other business-related inquiries.
1:31 Speaker 00 FH2 Pharma, your trusted partner for unique dosage formulations of generics, ensuring your pharmacy thrives in today's competitive market. Learn more at FH2Pharma.net. That's FH2Pharma.net. Tell them you learned about FH2 Pharma on the Pharmacy Podcast Network.
1:57 Speaker 01 Let's be real. Running a pharmacy has never been more complex. Rising employment costs, the struggle to find qualified staff, and an ever-expanding scope of practice are a lot to handle. Pharmacists today don't just dispense medications, they administer vaccines, prescribe treatments, and even conduct diagnostic tests.
2:17 Speaker 02 With all these added responsibilities, how do you keep your pharmacy running smoothly while remaining focused on patient care? Well, more and more pharmacies are turning to outsourcing, and for good reason.
2:28 Speaker 01 Imagine offloading your administrative workload, reducing recruitment overheads, benefiting from retrenchment, and focusing more on key business activities, all while keeping your pharmacy at the top of its game. Sounds pretty great, right?
2:43 Speaker 02 That's where Pharmastaff comes in. They specialize in non-clinical pharmacy staffing solutions, helping pharmacies streamline operations so you can focus on delivering exceptional patient care. So here's the big question: Is your pharmacy ready to explore the benefits of outsourcing? Running a pharmacy has its challenges, but what if you could streamline operations, save up to 78% on payroll costs, and focus on what truly matters most: your patients and the growth of your business?
3:12 Speaker 01 Discover the power of pharmacy outsourcing with Pharmastaff. Their specialized pharmacy staffing solutions are designed specifically for the pharmaceutical industry, helping you reduce administrative burdens, employment expenses, and improve efficiency.
3:26 Speaker 02 By partnering with Pharmastaff, you unlock a new level of operational excellence, allowing your team to stay focused on delivering exceptional patient care without the stress of managing back-office tasks.
3:39 Speaker 01 Learn more about how Pharmastaff can support your pharmacy. Schedule your meeting today by visiting us at pharmastaff.com. That's pharmastaff.com.
4:05 Speaker 03 Thanks for listening to the Pharmacy Podcast Network.
4:17 Speaker 03 Hello pharmacists, I'm Katrina Azar, busy mum, pharmacist, board member, writer, podcaster and CEO of the Australasian Precision Medicine Academy where I teach pharmacists and doctors how to bring pharmacogenomics to their practices. But you know what, it wasn't that long ago that I lacked the confidence and clarity to focus on growing my pharmacy career. Fast forward a few years and many failed attempts and you'll see the pharmacy career I have today, one that gives me more freedom and fulfillment than I ever thought possible, one that only existed in my daydreams. So I created the PharmXcel Podcast to help give you my dear pharmacist friends, simple and actionable insights to excel in your
5:00 Speaker 03 pharmacy career too. Insights that are not only clinically irrelevant, but that will grow your mindset and help you see past the four walls of the status cure of pharmacy practice. So if you're an ambitious pharmacist who's ready to excel in your pharmacy career, you're in the right place, friend. Let's get started.
5:29 Speaker 03 Globally, the incidence of medication-induced drug reactions is estimated at 50% to 6% of hospital admissions, with a significant portion of these occurring in low and middle income countries where unsafe care contributes to a high number of adverse drug events, potentially reaching 134 million annually and resulting in 2.6 million death. Studies suggest that between 2.5% and 10.6% of hospital admissions in Europe are due to adverse drug reactions, while in the United States it's estimated at 3.6%, but due to under-reporting the true incidence of adverse drug reactions is likely to be higher than reported statistics. In fact, it is known to be the fourth leading cause of death in the United States, factors
6:12 Speaker 03 like polypharmacy, medication interactions, all to Asia are among those that contribute to this.
6:17 Speaker 04 But an often overlooked factor is the patient's genetics. As pharmacists with our medication expertise, we are uniquely positioned to reduce adverse drug reactions and enhance medication safety with the tools such as pharmacogenomics, a field that tailors drug therapy based on individual's therapeutic profile, powerful tools to optimize treatment and minimize harm. Pharmacists are the medication experts at the forefront of patient care, bridging the gap between pharmacogenomics and its practical application. By integrating pharmacogenomics into clinical practice, we can personalize therapy, reduce trial and error risk quality, and ultimately improve patient outcomes. But what does it take to adopt pharmacogenomics in clinical pharmacy practice?
7:00 Speaker 04 How can we navigate this implementation and what skills do we need to drive this transformation in healthcare? Join me today for an amazing discussion with my guests.
7:09 Speaker 05 Hello, everybody. Welcome to another episode of the PharmExile Podcast. Today, I'm joined by two experts who are actively shaping the future of precision medicine in pharmacy practice. They'll share insights on how pharmacists can embrace this field, overcome barriers, and become champions of precision medicine in their communities. Pharmacogenomics is not mystique or sci-fi. This is something that is happening, and we need you on board. So please stay with us through this podcast, and we'll share some valuable insights. Let us welcome our guests for today. I'll hand over to Christine. Christine, let us know about yourself. Sure, I'm Christine Ashcraft. I have now been in pharmacogenomics for 25 years, started MY4A in 2000 at one of the
7:51 Speaker 05 first CLIA-accredited labs to offer testing in the country, and it's long past time that this is standard of care. Absolutely. And then we hand over to Burns. Burns, let us know what you're all about.
8:03 Speaker 06 Sure. Dr. Burns Blackshaw, my first exposure to pharmacogenomics was in the mid-'90s during my PhD training, when we found one of the early genetic mutations that meant people failed a clinical trial for a beta blocker. And I've been using genetics to identify novel diagnostic therapeutics ever since. Really passionate about implementing precision medicine in health systems and with providers. And really key to our podcast today is democratizing pharmacogenomics for all, because I think that's the goal.
8:43 Speaker 05 Brilliant.
8:45 Speaker 03 I am a pharmacist and I have no idea what this big, long word means. Can you tell me a little bit about it and why it is important right now?
8:54 Speaker 06 Yeah, absolutely. It's a great question. Quite often, we get scared when we hear words we don't know because we think we're smart pharmacists or pharmacologists like myself or physicians, providers. Pharmacogenomics sounds really big, but it really just means making sure that your DNA matches your medications.
9:17 Speaker 06 So I think a really sobering fact is that in the United States, for example, the fourth leading cause of death after cardiovascular disease, cancer and stroke is actually adverse drug events. So our intent to treat is often sadly a cause of death if we don't pay attention to the way that not only drugs interact with each other, but how they interact with our genes. And as a patient receives a pharmacogenomic test and a pharmacist, we believe pharmacists should be central to this, optimizes not only the drug-drug, but the drug-gene interactions. We can really optimize outcomes and we may have a chance to talk later in the podcast
10:01 Speaker 06 about a number of publications that we and others have had showing that it can truly not only optimize outcomes, reduce ER visits, hospitalizations, but also reduce cost of care.
10:11 Speaker 03 Absolutely. And Christine, tell me, what is the biggest myth you hear pharmacists or health practitioners say about pharmacogenomics that holds back people from implementing this in practice?
10:24 Speaker 05 I think to your point, a lot of people are like, "Ooh, big scary word. I don't have the training or understanding. I didn't learn about this." And I would say if people have an understanding of drug-drug interactions, then they intuitively understand drug-gene interactions. The FDA and Drug Development Guidance for decades provided a list of drugs to make a patient as if they were a poor metabolizer or an ultra-rapid metabolizer. You may remember from pharmacy school inhibitors and inducers, either potent or moderate.
11:01 Speaker 05 Having pharmacogenetic variations are essentially like having inhibitors or inducers that can never go away. This is a very simple, natural extension of what we do. And I think sometimes people get bogged down in the "star one, star four, cytochrome B450, 2D6." Like, sure, there's a lot of terminology, but at the end of the day, I like to, you know, maybe slightly oversimplify it, but we are pretending everybody has two lanes of mainly the cytochrome highways that process medications, when genetically, some of us have one lane, three lanes, or no lane at all. And having that information really helps us optimize drug inducer selection.
11:45 Speaker 03 That is such a great way of putting it, because a lot of pharmacists do get overwhelmed by that. And I think they, I think a lot of pharmacists don't know that actually, you know, labs like XsDX and other labs, they actually tell you pretty much what to do on the report. So you don't actually need to do much in the way of thinking, "Oh, what do I do now?" It's more about combining your knowledge of pharmacology, drug interactions, and bringing in the genetic component. So it's just another biomarker, really, that we can use to optimize medication outcomes. So yes, it might come across as a massive, big, long word, but it is just business as usual. If you, when you try to implement it in practice, it is just business as usual.
12:29 Speaker 03 So it's not anything that a common job logs pharmacist wouldn't know what to do. So I'm really, you know, it's a great way to put, to put it and explain it that way, that it's a lot less overwhelming that what it seems. So Brins, back to you. You've completed a number of publications that shows that PGX can optimize patient care and medication outcomes. Can you highlight a few of those publications that you've mentioned and the main takeaway messages?
12:55 Speaker 06 Sure, so I've had the pleasure of publishing a number with Christine. And one that I'll highlight just for people's reference is a publication we had a couple of years ago that actually talked about implementing PGX into a health practice. So I'll refer people to that one. But some prior studies from Christine and others in our group and then groups across the world have demonstrated all sorts of positive impacts. So the recent Prepare trial from Europe in 7,000 patients demonstrated that a 12-gene pharmacogenetic panel that had some decision support along with it, so it didn't become overwhelming
13:37 Speaker 06 for anybody, could reduce adverse drug events by 30% over the course of 12 weeks. And in prior work, in a four-month study in 65 and older Medicare population, demonstrated that by using pharmacogenomics plus a robust clinical decision support tool could reduce ER visits and hospitalizations somewhere from 30 to 70%. And there was an in-home study done as well where it showed that it could reduce, again,
14:19 Speaker 06 ER visits, hospitalizations, and even the cost of care quite dramatically. So in the study I was mentioning before, cost of care was reduced to over $1,000 in these really acute patients with in-home pharmacist visits was somewhere in the realm of $4,000 in just 60 days in savings plus optimizing outcomes. So there are a lot of studies, they're not just ours, they're from other groups demonstrating a really robust impact on optimizing health outcomes and reducing cost of care. We already know from other work done in pharmacy previously that de-prescribing can be very helpful.
15:03 Speaker 06 I'm sure all of us, if listening, if we've done anything with care of patients in their medication lists, know that it's not uncommon to see a patient who has 13, 20 medications prescribed by eight to 10 different providers. And again, this is where we believe that pharmacists are really key, is that central nexus of optimizing medication management using drug-drug, as well as drug-gene interactions to optimize care across the care team.
15:32 Speaker 03 And you've worked with a group of pharmacists at Christ Hospital, I believe, and you're going to tell us all about that project and exact steps of how you did that, so that other pharmacists can do it too, inside the ElevateRx.live summit. So people who join us, and I'm going to put a link to that in the podcast notes, for those interested in pursuing pharmacogenomics in their practice. But, yes, you're absolutely correct, in that there is a lot of evidence, there is a lot of research. We do have the backup. That brings me to the challenges. Do you think, either of you, is this purely just a reimbursement case of this is not reimbursed? Or what do you think are the real barriers here? I believe, obviously, awareness and
16:15 Speaker 03 education is one big barrier, and this is exactly why we have the ElevateRx Pharmacogenomics Summit coming up on April 12, 12:00 p.m. to 6:00 p.m. But what else? Where is the problem?
16:27 Speaker 05 Yeah. There, I think it's a multi-pronged problem, like many problems are. So reimbursement is an issue, but Medicare in the States has covered pharmacogenetic testing aligned with CPIC and FDA guidance since 2020. Thanks to biomarker legislation, commercial and Medicaid has followed suit with that coverage in 20 states and growing. So that's starting to be addressed. You also have the education issue. Ideally, we get the Right Drug Dose Now Act reintroduced again this year and actually passed. Please ask your congressional representatives to co-sponsor reintroduction of this bill, but it would invest in healthcare provider education across the board, because most people do not know what a big problem adversary
17:12 Speaker 05 Drug events are and how big of a piece pharmacogenomics can play in reducing patient harm and reducing healthcare spend. So spreading the word both to patients and providers is key. The other thing though is technology. I have been involved in Uscript Clinical Decision Support and some iteration for a very long time. And that came about because I used to be in charge of sales and marketing for one of the first labs to offer testing. And of course, our providers will be like, well, how do I know who to test? How do I know how to act on that? And integrating something in the clinical workflow that says, hey, test this patient, it would be helpful. Hey, this is how you very quickly
17:54 Speaker 05 find another drug that would be more appropriate to them or understand how to adjust the dose. It's great to, you know, have reports or drive people to clinical decision support in an ordering portal that they can access through the lab. But the ideal thing is to put it in the workflow. And that's another thing that the Right Drug Dose Now Act would do. Hit the easy button. Make it easy for people to leverage tools that can help us improve patient safety and care.
18:21 Speaker 03 Absolutely. That is a major barrier. And I think, you know, even you combine all those factors together, you know, the lack of workflow integration and then combined with the lack of awareness and then the perceived reimbursement challenges, some of them are real in some states, you then you really hit a stumbling block and you think, okay, this is just too hard. I'll just take the easy part of it. I'll stick with the status cure because it's safe and I know what I'm doing. Have any of you ever, you know, approached universities to understand, like, I'm obviously not in the United States, what is the standard of pharmacogenomics in undergraduate education? Because I know that some of them have postgraduate programs, but I just feel like that's a little bit too late. You know, you want to kind
19:06 Speaker 03 of embed these principles earlier on in the educational journey, pharmacists and doctors. So do you have any experience with that? Or have you approached universities to tackle this problem in awareness and education?
19:20 Speaker 06 Yeah, I, so I still have an adjunct appointment and I'm very active in education. If I could, before we get to that, I'm just going to go back to the question that you asked Christine and I. Christine gave a wonderful answer. I think from an adoption standpoint,
19:38 Speaker 06 Another, another major hurdle is that, in our opinion, again, pharmacist at the center, the core, but also a broad panel test. You want to make sure that you're testing for all of the gene-drug interactions that you should be looking for. And then you have the adoption problem from a physician's standpoint of what if the drug that's impacted is not the one that I'm managing? What's my liability then?
20:11 Speaker 03 Yeah.
20:12 Speaker 06 And then that becomes a real sticking point for, for the adoption as well, because they don't want that liability of managing a medication.
20:22 Speaker 03 Perceived.
20:23 Speaker 06 Yeah, perceived liability. Thank you, Christine. So back to the education standpoint, you know, we have significant challenges because right now pharmacogenomics is not even part of medical school curricula. And even in pharmacy school, it's a, it's a relatively minimal part of most curricula. So I would love to go back to the, you know, the earlier stages of undergrad education or even high school. And I do get invited to participate in those on a regular basis. I would love for the education to be for everyone, and I would love for it to start early. But I think right now, just having the efforts
21:08 Speaker 06 of getting it into medical school education so that when you, as the pharmacist, are speaking with the physician, that their training has actually included what you want to talk about. So I love the idea of education, and Christine and I and others have all done a lot of advocacy work and work on this Right Drug Dose Now Act that Christine has worked on, you know, fervently for quite some time now.
21:38 Speaker 06 But, you know, we have to start somewhere. And I think that the starting somewhere right now is making sure that the practitioners, the pharmacists and the physicians at least have an understanding. And then maybe it's time for the public to understand as well. And we probably haven't done a great job educating the public yet on this big, long word that can actually optimize their health.
22:00 Speaker 05 We now talk about it at cocktail parties every time I'm at one. And pretty much everybody I tell pharmacogenomics by explaining, they're like, oh, everybody should do this.
22:10 Speaker 03 I know. This is exactly the direction you get from every... I was like, but why did my doctor not tell me about this? And then it's a very hard situation because when I first started pharmacogenomics and I got that comment, and I have received that comment from probably 90% of my patients, like, but if this is so important, why is it not standard of care? And then you kind of pause and you think, well, I don't really want to blame it on the sound system and I don't really want to blame it on the doctor that they don't... And you don't want to blame it on anyone. It's like, but you also don't want to say there's no evidence. That's why it's just really early on. So it's a really... That's a really complex question to navigate. What do you think?
22:51 Speaker 05 I do think part of the issue is the silos that patient care is divided in. So I go to my PCP and then they're like, oh, you're diabetic. Go see an endocrinologist. Oh, you're depressed. Go see a psychiatrist. Oh, you're da-da-da. Great. So now you have all these specialists and they do different things. And God forbid you get cancer, now you have an oncologist. And so all of these people are prescribing medications. Nobody's writing proper hurt on it, right? And then pharmacogenomics impacts all of these medications and all of these different areas. And the specialist that can manage that is a pharmacist. And part of the issue, at least in the US, is that pharmacists are not federally recognized as healthcare providers, even though they have just as much education to get a PharmD
23:35 Speaker 05 degree as an MD. Like, you go to school a long time. These should be recognized healthcare providers. PAs don't go to school that long. Nurses don't go to school that long. Like, it doesn't make sense. But those are the healthcare specialists that should be optimizing medications. I think of polypharmacy as if it were a disease state. And we should be fighting it as if it is the worst disease state we are dealing with because frankly, it is. Um, pharmacists should be getting paid to do reviews. There are paths to do that to optimize these medications, including incorporating PGX. But I think they can help
24:16 Speaker 05 us overcome the silos, and that's part of the issue we've dealt with across so many.
24:22 Speaker 06 Yeah, I think there's also, Katrina, a recent study out of the UK where they are trying to implement panel pharmacogenomic testing by the end of the year.
24:34 Speaker 05 Yeah.
24:35 Speaker 06 And, and this study was really great because they, and this is exactly the same as Christine's experience at cocktail parties and mine and so many others, is that nobody really knows what it is. But when people learn what it is, greater than 90% of them would like to do it. So, part of our role is education to drive adoption. Sometimes the best advocacy is walking into the doctor's office and saying, I want to do this. So, it's, and, and perhaps our best work is to help pharmacists understand this so that
25:17 Speaker 06 they can work with patients to then convince practitioners who got no training on this when they trained 20 years ago, to try to help optimize care across the care team with the pharmacist at the core.
25:30 Speaker 05 Absolutely. Berns, this came up earlier today, and I thought it was a great point, how when you had embedded pharmacists, at first, there was some resistance, and then by the end, they were like, you will take, I think that the quote was, you will take my pharmacist away over my cold, dead body. But, all healthcare providers are burnt out. Like pharmacists can help with this burnout issue. They can come in and help reduce burden and optimize care, and we need to remove that. Like, this, this behooves everybody. It helps the healthcare providers. It helps the patients. It doesn't make any sense that there are barriers to enabling pharmacists to do this more broadly.
26:14 Speaker 03 You know, I think you've hit the nail on the head, because I don't think it has so much, like, we've discussed the awareness and education piece, but there is the empowerment piece that pharmacists need, and not wishing to promote the academy. That you know that I've put together, but
26:31 Speaker 03 quarter. So the academy has three parts, the clinical knowledge, which is part one, part two and part three are purely business empowerment. This is how you go out and speak about PGX to the communities. This is what you say to the doctors. Here is a presentation with all the data. This is exactly what you need to say. So it's like, and sadly, when you have been through, I don't know, six, seven years of university, you kind of get used to being spoon fed everything. Like, I think this is what pharmacists are kind of looking for, the empowerment phase. You can actually do this. This is your expertise. This is within your realm. But this is also how you do it. This is step by step how you approach this, which is really something that we're trying to do with the event.
27:13 Speaker 03 Um, that we created, but yeah, like you said, pharmacists need to be empowered to help doctors with burnout. And I think part of it is also you will probably come across in pharmacy, there's a lot of um tension in between pharmacists and doctors. It's not often something that can easily be overcome. Like if you can just get in through the door, that's a huge step. Now, now you build that relationship. And I think that's actually really important point is you don't go attacking them with PGX straight away. You kind of have to build that relationship, showing them the value of pharmacists, of medicines reconciliations, of medications reviews and CEMMs and all that.
27:52 Speaker 03 And then you bring in PGX, because if you approach it from the start, it's going to be, oh my God, like this is just far too complicated. I can't do all of this. You can't send me a report with three hundred recommendations on it. What do I do with this sort of thing?
28:07 Speaker 06 Yeah, Katrina, that was, we'll talk about it more during the elevator summit, but that was exactly our experience. Our pharmacists were introduced simply for hypertension, diabetes, medication management for nearly a year before we introduced the word pharmacogenomics. Uh, because you need to build that relationship. So part of, part of the goal is education and developing the relationship of trust to where.
28:38 Speaker 06 The provider doesn't feel threatened by a pharmacist stepping on their territory. And ultimately, like Christine mentioned, comes to see the value of the pharmacist because they can do medic-- they get five times the training any physician does in medication management during-- for a residency-trained pharmacist. So sooner or later, people, providers can appreciate the benefit of that in their practice. And like Christine and you were both saying, reduce the burnout that is happening across all clinical care.
29:13 Speaker 03 Absolutely. And I'm a pharmacist and I work in a community pharmacy setting. And I feel like this is far too complex to implement in community pharmacy. What are your opinions? What do you think?
29:25 Speaker 06 Oh, boy. That's an interesting question.
29:29 Speaker 05 Do you drug interaction management in clinical pharmacy? As I said earlier, it's the same thing. If you can manage drug-drug, you can manage drug-gene, you can manage multi-factor. Uscript, clinical decision support tool. We used to have a team of pharmacists and they created these personalized prescribing reports based on genetic test results and the medications and herbals and over the counters a patient was taking, things like beer's criteria, smoking. And it used to take about 20 to 30 minutes on average for our pharmacists to create these personalized recommendations when patients were tested. We kept upgrading and improving Uscript and automating things.
30:10 Speaker 05 And we brought our time down to two to three minutes per patient, on average taking almost nine medications to provide personalized guidance to providers to help optimize that patient's care. It's so incredibly helpful. Even when you automate the heck out of things, you still need a pharmacist to go, hey, we need to change this medication or maybe we can stop it. This patient's been on it for six years. It hasn't done a thing. Why are they even on it at all? Stop. Or, hey, we need to find an alternative medication. These two are the best options, or this one is the best option. That piece in there, it saves time, it improves care. But those kinds of tools, they're there to make life easier. They're useful.
30:53 Speaker 03 Absolutely. And--
30:57 Speaker 03 Let's round it up with the last question. If a pharmacist is sitting on the fence about attending the Elevator X Pharmacogenomics Summit, what would you tell them?
31:10 Speaker 06 We're cool.
31:12 Speaker 03 Absolutely.
31:15 Speaker 03 You need to join because we're cool.
31:17 Speaker 06 Yeah. Come hang out with the cool kids.
31:22 Speaker 06 You know, I think the the simple reality is all of us are educated and me and a pharmacist and anyone else, if I could get paid to continually educate myself, I would do that. That would be the greatest job ever. So this is a great opportunity to expand your horizons and understand that this big word that might seem scary is really just an extension of what you're already doing as a pharmacist and can really help optimize the care that you can provide. And then, you know, in partnership with your academy and others, you can learn how to implement this.
32:06 Speaker 06 So implementation is probably the last but most difficult mile or kilometer.
32:12 Speaker 03 But you're making it easy, right? You've got X, XDX and Uscript and all those amazing tools we've just talked about. It's actually not as hard and we can implement this.
32:21 Speaker 06 Exactly. Yeah, so I think from my perspective, we are here to help make big word become easy button.
32:30 Speaker 03 Absolutely.
32:31 Speaker 05 And to that to that end, I just shared the PGx track at PMWC and a pharmacist that implemented at a cancer center really helped lead the charge there. It was like, you know, don't let perfection be the enemy of good. Just get started. And so I will be talking about good, better, best. Sure, best is integrated clinical decision support right in the pharmacy software system or EHR. Great, we don't need that. There are tools we can use that help us do this for some of our patients when it is most impactful and the key is really just to start somewhere, not to let perfection slow you down.
33:14 Speaker 03 And the reality is that I'm not, I don't know, maybe you know the answer to this, but I don't know if a single healthcare system that has all of that integrated into it anyway, like even here in New Zealand, this is like. But in cities, we don't have shared records.
33:30 Speaker 03 But yeah, it is a challenge. So absolutely, if you're going to wait for technology to support this, it's not, never going to happen.
33:38 Speaker 05 I don't know about New Zealand, but we still fax things here.
33:41 Speaker 03 No, we don't. We're... Gosh, you guys are living in the dreadful past. No, we don't. We've thrown away the fax machines. They don't hardly sell them anywhere anymore.
33:56 Speaker 06 Perfect.
33:57 Speaker 03 Yeah, but no, I guess on that note, I just want to share, I guess, one of my academy students, and this is probably the most profound story and probably one that many pharmacists will resonate with who are listening to this, is she PGX tested a patient who had, was going to have their eighth stent. And they were, so that was her first patient. She, they were on like 13 medications and yeah, upcoming eighth stent and they were a Cephalococcal C19 or metabolizer and they were on clopidogrel. So they could have died. So for those of you listening who don't know, that means they're not actually converting clopidogrel to the active form and they needed alternative therapy and she recommended that, but they just came at the right time. And
34:42 Speaker 03 that's probably one of the most profound stories. You know, how many stents does one need before they realize something is wrong and this is not working? So yeah, absolutely would encourage everybody listening to attend. Thank you guys for being here, for your time. I really appreciate it. And please come and join us. Come and join Christine and Burns at the Elevator XPDX Summit. I'll put the link in the show notes. It's been a pleasure to talk to you both. Thank you so much for your time.
35:09 Speaker 05 Thank you so much.
35:10 Speaker 06 Always a pleasure.
Previous APhA 2025 Preview & the Expanding Roles of Pharmacists | TWIRx Next Cannabis Education with Sang Choi RPH of the NYS Office of Cannabis Management | The Answer Page Podcast Page updated November 15, 2026 · transcript and summary are machine-generated